Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com

March 29, 2019 3:00 PM JST
Chordia Therapeutics Raises Approximately 27 million USD in Series B Financing•Chordia Therapeutics Inc., an oncology research and development company basedin Kanagawa, Japan, closed the first tranche of its approximately 3.0B JPY (27MUSD) Series B financing.

Kanagawa, Japan, March 29, 2019 – Chordia Therapeutics Inc. (“Chordia”), an oncology
research and development company, today announced the completion of the first trancheof its Series B financing to advance its lead asset, CTX-712, a selective pan-CDC-likekinase (“CLK”) inhibitor currently in Phase I and accelerate other pre-clinical programs
towards clinical trials. The financing was co-led by Kyoto University Innovation Capital(“KYOTO-iCAP”) and JAFCO, with participation from Shinsei Capital Partners,
Mitsubishi UFJ Capital, SMBC Venture Capital and Nippon Venture Capital.
Hiroshi Miyake, Ph.D., representative director of Chordia said, “I am delighted that thefinancing enables us to accelerate development of our clinical and pre-clinical assets. Our
mission is to deliver transformative therapeutic medicines to cancer patients.”“CLK is a kinase that regulates RNA splicing, which is a fundamental biological process
for cells. CTX-712, a novel, first-in-class, small-molecule pan-CLK inhibitor inducessynthetic lethality to cancer cells with vulnerability in splicing reactions in pre-clinicalstudies. The Phase I clinical trial is underway to evaluate the safety, tolerability,
pharmacokinetics and efficacy of CTX-712.”
Details of the clinical trial are available at:https://www.clinicaltrials.jp/cti-user/trial/ShowDirect.jsp?clinicalTrialId=21991
Hiroyuki Ueno, Ph.D., director of Chordia and investment officer of KYOTO-iCAP said,“I hope that this financing will accelerate the development of Chordia’s pipeline assets
and they will benefit cancer patients and their families in the near future. I expect Chordia
to continue pursuing patient-centric R&D through industry‐academia‐government
collaboration and become a global company, based in Japan.”
Chordia was launched at Takeda Pharmaceutical Company’s Shonan Health Innovation
Park (“Shonan iPark”) in October 2017. With approximately 1.2B JPY (11M USD) ofChordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com

Series A funding, CTX-712 entered Phase I clinical trials in November 2018. In addition
to CTX-712, Chordia has three pre-clinical assets in the pipeline, and continues its drug
discovery campaign in the state-of-the-art research facilities at Shonan iPark.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 paracaspase(“MALT1”) has a central role in antigen-dependent responses and NF-κB activation inlymphocytes. Inhibiting MALT1 is expected to be a potential approach for the treatmentof a variety of lymphomas. Cyclin-dependent kinases 12 (“CDK12”) phosphorylates theRNA polymerase II carboxy-terminal domain to regulate transcriptional elongation,splicing, and polyadenylation. Inhibiting CDK12 is expected to abrogate expression ofDNA repair genes and suppress cancer cell survival and proliferation. General control
nonderepressible 2 (“GCN2”) kinase senses amino acid availability. GCN2 inhibitors areexpected to work synergistically with amino acid depletion agents and cancer
immunotherapeutic drugs.
Miyake said, “We are passionate to explore new therapeutic options in oncology areas
with high unmet medical needs. Our second asset, MALT1 is currently in the pre-clinicalstage, and is expected to start clinical trials in 2020.”
For more information, contact info@chordiatherapeutics.com